AIM20 Antibody

What is AIM2 and why is it important in immunological research?

AIM2 (Absent in Melanoma 2) is an IFN-inducible protein that functions as an intracellular DNA sensor involved in innate immune recognition. It serves as a host sensor against a wide range of infections and plays a critical role in inflammasome activation. Upon binding to double-stranded DNA, AIM2 initiates the formation of an inflammasome complex through its pyrin domain interaction with the adaptor protein ASC. This activation subsequently leads to caspase-1 activation, which cleaves pro-inflammatory cytokine precursors pro-IL-1β and pro-IL-18 into their active forms. Additionally, AIM2 inflammasome activation can trigger pyroptosis, a form of programmed cell death. The AIM2 inflammasome has been implicated in responses to various pathogens, cancers, and inflammatory diseases, making it a significant target for immunological research .

How does AIM2 expression differ across human cell types?

AIM2 shows a maturation-dependent expression pattern in human immune cells. Research has demonstrated that functional AIM2 is preferentially expressed in adult human CD27+ B-cells but is notably absent in cord blood mononuclear cells. This differential expression suggests developmental regulation of AIM2 during immune system maturation. Flow cytometry analysis has confirmed this finding using specific monoclonal antibodies against AIM2, with additional markers such as CD19, CD27, CD3, and CD56 to identify different cell populations. The cell type-specific expression pattern of AIM2 has important implications for understanding its role in various immune responses and potentially age-dependent susceptibility to certain infections or inflammatory conditions .

What are the validated methods for detecting AIM2 protein in human samples?

There are several validated methods for detecting AIM2 protein in human samples, each with specific applications depending on research objectives:

• Flow Cytometry: This technique allows for the detection of AIM2 protein at the single-cell level. Using PE-conjugated anti-AIM2 monoclonal antibodies (such as those from Biolegend, cat no. 652803) at a 1:20 dilution, researchers can quantify AIM2 expression in specific cell populations when combined with other cell surface markers. Flow cytometry is particularly useful for investigating AIM2 expression across different immune cell subsets .

• Western Blot Analysis: For quantitative protein expression analysis, Western blot using whole cell lysates provides reliable detection of AIM2. This method typically employs rabbit monoclonal anti-AIM2 antibodies (such as CST #12948) at a 1:500 dilution, followed by HRP-conjugated secondary antibodies. Protein bands are visualized using enhanced chemiluminescence. Western blot is effective for comparing AIM2 expression levels between different experimental conditions or cell types .

• Immunohistochemistry/Immunofluorescence: Though not explicitly mentioned in the search results, these techniques are commonly used to detect AIM2 in tissue sections or fixed cells, providing information about its spatial distribution.

Each method offers different advantages in terms of sensitivity, specificity, and the ability to analyze AIM2 in the context of other cellular markers or proteins.

How can researchers optimize AIM2 antibody detection in flow cytometry?

Optimizing AIM2 antibody detection in flow cytometry requires careful consideration of several factors:

• Antibody Selection: Choose a validated anti-AIM2 monoclonal antibody with high specificity. PE-conjugated anti-AIM2 antibodies (Biolegend, cat no. 652803) have been successfully used in research at a 1:20 dilution .

• Proper Controls: Always include an isotype control (e.g., IgGκ-PE, Biolegend, cat no. 400135) at the same concentration as the AIM2 antibody to assess background staining and non-specific binding .

• Cell Fixation and Permeabilization: Since AIM2 is an intracellular protein, use appropriate fixation and permeabilization protocols to ensure antibody access while preserving epitope integrity.

• Multiparameter Analysis: Combine AIM2 staining with lineage markers such as CD19 for B cells, CD3 for T cells, and CD56 for NK cells to accurately identify AIM2 expression in specific cell populations .

• Cell Isolation Quality: Ensure high viability of isolated cells and minimize cell activation during processing, as this may affect AIM2 expression levels.

• Titration of Antibodies: Perform antibody titration experiments to determine the optimal concentration that provides the best signal-to-noise ratio.

• Instrument Settings: Properly set compensation controls when using multiple fluorochromes to correct for spectral overlap.

These optimization steps will enhance the reliability and sensitivity of AIM2 detection in flow cytometry experiments.

What is the relationship between B-cell maturation and AIM2 expression?

Research has established a clear relationship between B-cell maturation and AIM2 expression. Studies demonstrate that functional AIM2 is preferentially expressed in adult human CD27+ B-cells, which are typically memory B cells, but is absent in cord blood mononuclear cells. This maturation-dependent expression pattern suggests that AIM2 may play a role in the functional development of the adaptive immune system .

The differential expression between naive and memory B cells, as well as between neonatal and adult B cells, indicates that AIM2 expression is regulated during B-cell development and differentiation. This pattern may reflect the evolutionary advantage of controlled inflammasome activation, potentially preventing excessive inflammatory responses during early development while allowing for appropriate pathogen recognition in matured immune cells .

The mechanisms controlling this developmental regulation of AIM2 expression remain an area of active investigation, but may involve epigenetic modifications, transcription factor availability, or microRNA-mediated regulation during B-cell maturation.

How does the AIM2 inflammasome formation differ from other inflammasome complexes?

The AIM2 inflammasome has several distinguishing features compared to other inflammasome complexes:

• Activation Trigger: While NLRP3 inflammasomes respond to a diverse range of stimuli including cellular stress signals and PAMPs (Pathogen-Associated Molecular Patterns), AIM2 is specifically activated by double-stranded DNA in the cytoplasm, making it a dedicated cytosolic DNA sensor .

• Structural Components: AIM2 contains a DNA-binding HIN200 domain that directly binds to cytosolic dsDNA without requiring intermediate proteins. This direct binding mechanism differs from other inflammasomes like NLRP3, which rely on indirect sensing mechanisms .

• Assembly Process: Upon dsDNA binding, AIM2 undergoes conformational changes that expose its pyrin domain, allowing it to interact with the adaptor protein ASC. The carboxy-terminal CARD of ASC then binds to the CARD of pro-caspase-1, leading to caspase-1 activation and subsequent processing of pro-IL-1β and pro-IL-18 .

• Cellular Distribution: AIM2 shows cell type-specific expression patterns, being predominantly present in certain mature immune cells like CD27+ B cells but absent in cord blood mononuclear cells. This restricted distribution differs from some other inflammasome components that may be more widely expressed .

Understanding these distinct features of AIM2 inflammasome formation is crucial for developing targeted research approaches and potential therapeutic interventions for conditions involving aberrant inflammasome activation.

How can the acoustofluidic integrated molecular diagnostics (AIMDx) platform be adapted for AIM2 antibody detection?

The acoustofluidic integrated molecular diagnostics (AIMDx) platform represents an innovative approach that could be adapted for AIM2 antibody detection in research applications. While the platform was originally developed for detecting viral antibodies and nucleic acids, its principles can be applied to AIM2 research:

• Sample Purification: The AIMDx platform uses acoustic vortexes and Gor'kov potential wells at a subwavelength scale to isolate biological components from complex samples. This approach could be modified to concentrate cells expressing AIM2 or to isolate AIM2-containing complexes from clinical or experimental samples .

• Multiplex Detection Capabilities: The platform's ability to simultaneously detect multiple antibody classes (IgA, IgG, IgM) could be leveraged to detect different forms of AIM2 complexes or to examine AIM2 interactions with other inflammasome components in a single assay .

• Enhanced Sensitivity: AIMDx has demonstrated sensitivity down to 15.6 picograms per milliliter for antibody detection, which could enable the detection of low-abundance AIM2 in various experimental conditions or patient samples .

• Electrochemical Sensing Adaptation: The electrochemical sensing components could be modified with specific capture molecules (e.g., anti-AIM2 antibodies or known AIM2-binding DNA sequences) to create a rapid detection system for AIM2 or its activation state .

• On-chip Processing: The platform's capacity for on-chip purification and detection could be particularly valuable for working with limited sample volumes or for maintaining native protein interactions during processing .

Adapting this technology would require careful optimization of capture molecules, flow parameters, and detection settings specific to AIM2, but could potentially provide a powerful tool for high-throughput, sensitive AIM2 research applications.

What are the challenges in developing cross-reactive antibodies for AIM2 detection across different species?

Developing cross-reactive antibodies for AIM2 detection across different species presents several significant challenges:

• Sequence Divergence: AIM2 exhibits varying degrees of sequence homology across species. Researchers must identify conserved epitopes that are sufficiently preserved across target species while still being unique to AIM2 to avoid cross-reactivity with other HIN200 family proteins.

• Structural Differences: Even when sequence homology exists, subtle differences in protein folding or post-translational modifications between species may affect antibody binding. These structural variations can render an antibody effective in one species but ineffective in another.

• Validation Complexity: Each cross-reactive antibody must be rigorously validated in multiple species, requiring access to positive and negative control samples from each target species. This validation process is time-consuming and resource-intensive.

• Differential Expression Patterns: As demonstrated by the maturation-dependent expression of AIM2 in human B-cells, expression patterns may vary not only between species but also between developmental stages and cell types within each species . This variation complicates the interpretation of cross-species studies.

• Functional Conservation Assessment: Beyond mere detection, researchers must determine whether the antibody can recognize functionally equivalent forms of AIM2 across species, particularly if studying inflammasome activation or inhibition.

• Application-Specific Requirements: Different detection methods (flow cytometry, Western blot, immunohistochemistry) may require antibodies with different properties, potentially necessitating the development of multiple cross-reactive antibodies for comprehensive research.

To address these challenges, researchers often employ epitope mapping, recombinant protein expression systems, and extensive cross-validation approaches to develop and characterize truly cross-reactive AIM2 antibodies.

How can AIM2 antibody detection be integrated into viral immunity assessment?

Integrating AIM2 antibody detection into viral immunity assessment offers a novel dimension to understanding host immune responses. This integration can be implemented through several strategic approaches:

• Temporal Profiling During Infection: By monitoring AIM2 expression levels at different stages of viral infection, researchers can establish correlations between AIM2 activity and disease progression. Similar to the profiling of anti-SARS-CoV-2 antibodies shown in Figure 4I of the AIMDx study, a temporal mapping of AIM2 expression could reveal its role in different phases of infection .

• Cell Type-Specific Analysis: Since AIM2 is preferentially expressed in specific immune cell populations, particularly mature CD27+ B cells , combining AIM2 detection with cell-specific markers can provide insights into which immune cell subsets are actively engaging DNA-sensing mechanisms during viral infections.

• Correlation with Other Immunity Markers: AIM2 detection can be paired with measurements of antiviral antibodies, cytokine profiles, and cellular activation markers to create comprehensive immunity profiles. This multidimensional approach could help identify patterns associated with effective viral clearance versus pathological inflammation.

• Integration with Nucleic Acid Detection Platforms: Technologies like AIMDx demonstrate the feasibility of simultaneously detecting viral nucleic acids and host antibody responses . A similar approach could incorporate AIM2 detection alongside viral genome quantification to directly link viral load with inflammasome activation.

• Assessment of Inflammasome Functionality: Beyond measuring AIM2 protein levels, assays that detect downstream products like active caspase-1, IL-1β, or IL-18 could provide functional correlation with AIM2 expression, offering insights into the operational status of the inflammasome during viral infections.

This integrated approach would provide a more comprehensive understanding of how DNA-sensing mechanisms contribute to antiviral immunity and potentially identify new correlates of protection or pathology.

What is the potential role of AIM2 antibodies in monitoring inflammasome-related diseases?

AIM2 antibodies hold significant potential for monitoring inflammasome-related diseases through several mechanisms:

• Biomarker Development: Changes in AIM2 expression levels may serve as biomarkers for disease activity in conditions characterized by aberrant inflammasome activation. Quantitative measurements using AIM2 antibodies could help stratify patients and predict disease flares.

• Therapeutic Response Monitoring: In clinical trials of inflammasome inhibitors or immunomodulatory therapies, AIM2 antibody-based assays could provide pharmacodynamic endpoints to assess target engagement and biological response.

• Cell-Specific Inflammasome Profiling: The preferential expression of AIM2 in specific immune cell populations, such as CD27+ B cells , suggests that cell-specific inflammasome profiling using flow cytometry with AIM2 antibodies could identify precisely which cell types are contributing to pathological inflammation in different disease states.

• Assessment of Inflammasome Assembly: Advanced techniques using AIM2 antibodies, such as proximity ligation assays or co-immunoprecipitation, could enable monitoring of inflammasome assembly in patient samples, providing deeper insights into disease mechanisms beyond simple protein expression.

• Complementary Diagnostics: Combining AIM2 antibody detection with other inflammasome components (ASC, caspase-1) and products (IL-1β, IL-18) could create comprehensive inflammasome activation profiles that more accurately reflect disease activity than single biomarkers.

This approach could be particularly valuable in autoimmune conditions, certain inflammatory diseases, and infections where inflammasome activation contributes to pathology. The maturation-dependent expression of AIM2 also suggests potential applications in age-related inflammatory conditions, where monitoring changes in AIM2 expression might provide insights into immunosenescence and age-associated inflammation.

How do different antibody clones affect the detection specificity of AIM2 in various applications?

Different antibody clones can significantly impact the detection specificity of AIM2 across various applications due to several key factors:

• Epitope Recognition: Each antibody clone recognizes a specific epitope on the AIM2 protein. Clones targeting the HIN200 domain might detect AIM2 regardless of its activation state, while those targeting conformational epitopes might only recognize AIM2 in specific structural states (active vs. inactive) .

• Application-Specific Performance: Some clones perform optimally in certain applications but poorly in others. For example, the rabbit monoclonal anti-AIM2 antibody (CST #12948) used at 1:500 dilution has been validated for Western blot analysis , but the same clone might not be optimal for immunoprecipitation or flow cytometry.

• Cross-Reactivity Profiles: Different clones may exhibit varying degrees of cross-reactivity with other HIN200 family proteins or with AIM2 orthologs from different species. This is particularly important when studying AIM2 in animal models or when examining samples containing multiple HIN200 domain-containing proteins.

• Sensitivity to Protein Modifications: Some antibody clones may fail to recognize AIM2 when it undergoes post-translational modifications or conformational changes upon DNA binding or inflammasome formation. Others may specifically recognize only modified forms of AIM2.

• Buffer and Fixation Compatibility: Different clones show variable sensitivity to fixation methods and buffer conditions. For example, some antibodies perform well in flow cytometry after paraformaldehyde fixation, while others may require alternative fixation methods to preserve epitope recognition.

Researchers should carefully validate antibody clones for their specific applications, comparing multiple clones when possible and including appropriate positive and negative controls to ensure reliable and reproducible AIM2 detection.

What are the optimal sample preparation methods for preserving AIM2 antibody epitopes?

Preserving AIM2 antibody epitopes during sample preparation is crucial for reliable detection. The following methodological approaches have been validated for maintaining epitope integrity:

• Cell Lysis Protocols for Western Blotting:

  • Preparation of whole B cell lysates in hot 1% SDS has been successfully used for Western blot analysis .

  • Protein concentration determination using BCA protein assay kit ensures consistent loading.

  • Sample denaturation should be performed at appropriate temperatures (typically 95°C for 5 minutes) to fully expose epitopes without causing protein degradation.

• Cell Preparation for Flow Cytometry:

  • For intracellular AIM2 detection, gentle fixation methods are preferred to maintain epitope accessibility while preserving cellular architecture.

  • Permeabilization reagents should be optimized to allow antibody access to intracellular AIM2 without excessive protein extraction or epitope destruction.

  • Blocking with appropriate buffers (such as PBS-Tween with 5% bovine serum albumin) helps reduce non-specific binding .

• Preservation During Cell Isolation:

  • Minimize processing time between sample collection and analysis/fixation to prevent protein degradation.

  • Maintain samples at appropriate temperatures (typically 4°C) during processing to reduce enzymatic activity that might degrade epitopes.

  • Avoid excessive mechanical stress during cell isolation, which can trigger artifactual inflammasome activation.

• Storage Considerations:

  • For long-term storage, snap-freezing in liquid nitrogen followed by -80°C storage preserves most epitopes better than gradual freezing.

  • Avoid repeated freeze-thaw cycles, which can lead to protein denaturation and epitope destruction.

  • Consider adding protease inhibitors to samples intended for storage to prevent enzymatic degradation of AIM2.

• Tissue Sample Processing:

  • For tissue sections, optimal fixation time should be determined empirically, as overfixation can mask epitopes while underfixation may not preserve tissue architecture.

  • Antigen retrieval methods should be optimized specifically for AIM2 detection in fixed tissues.

These methodological considerations ensure that AIM2 epitopes remain accessible for antibody binding, leading to more reliable and reproducible experimental results across different detection platforms.